The 177Lu-labeled anti-MMR VHH significantly delayed tumor growth, which outcompeted the effects of currently used therapies, such as immune checkpoint inhibitors, anti-angiogenic therapy (anti-VEGFR2 mAbs), and chemotherapies (doxorubicin, paclitaxel) [97]. This evidence concerns the gene KDR and neoplasm.